Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ensysce Biosciences Inc

ENSC ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$0.37

▼ -1.19%

Market Cap $7.26M · Vol 68.90K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$7.26M

Micro Cap

Div Yield

N/A

EPS Growth

+72.61%

YoY

RSI (14)

58.24

Momentum

Beta

0.95

vs Market

52W High

$2.74

86.38% below

52W Low

$0.24

58.18% above

Volume

68.90K

Avg 942.99K

P/B

1.31

Price-to-book

ROE

N/A

Return on equity

Free Float

94.84%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Ensysce Biosciences Inc (ENSC) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ENSC pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-6.65%

+30.39%

+15.54%

-6.09%

YTD

-59.42%

-81.97%

-98.70%

-100.00%

Financials & Valuation

TTM · Annual

Total Revenue	$5.07M
Net Income	$-10,176,190.00
Revenue Growth (YoY)	-15.10%
Gross Margin	100.00%
Operating Margin	-202.12%
Net Profit Margin	-200.85%
ROE	N/A
ROA · ROIC	-155.96% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	0.46
P/B	1.31
P/FCF	N/A
EPS Growth	+72.61%
Outstanding Shares	19.46M

Technical Indicators

50-Day SMA	$0.31
200-Day SMA	$0.68
RSI (14)	58.24
Beta	0.95
52-Week High	$2.74
52-Week Low	$0.24

Volume Today	68.90K
Avg Daily Volume (30D)	942.99K
Relative Volume	0.07x
Volatility (10D)	132.51
Volatility (30D)	170.07
Free Float	94.84%

Analyst Consensus

N/A

Current Price $0.37

Mean Target $8.25

52W Low$0.24 52W High$2.74

Current

Target

$0.24 $2.74

Current Analyst target

+2,110.02% upside potential · 1 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00JFF4183

ISINUS2936025046

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.09% ONC BeOne Medicines AG +1.44% RVMD Revolution Medicines Inc -1.07% 068270.KS Celltrion Inc -0.93% ABVX Abivax SA -2.75%

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases.